BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Catalym closes $59M series B round for GDF-15 inhibitor
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Catalym closes $59M series B round for GDF-15 inhibitor
Nov. 10, 2020
By
Cormac Sheridan
No Comments
DUBLIN – Catalym GmbH pressed the accelerator on its growth differentiation factor 15 (GDF-15) inhibitor program by raising €50 million (US$59 million) in series B financing, which will fund a first-in-human study lined up to start before year-end.
BioWorld
Cancer
Series B